MyMD Pharmaceuticals Schedules Business Update Conference Call
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced a conference call scheduled for May 17th at 4:15 p.m. ET to discuss its clinical and drug development plans. The call can be accessed via a registration link or by dialing in. The company is focused on two therapeutic platforms: MYMD-1, aimed at treating autoimmune diseases, and Supera-CBD, a synthetic derivative of CBD targeting key receptors. The press release includes a cautionary statement regarding forward-looking statements that highlight various risks associated with MyMD's pharmaceutical candidates.
- Scheduled a conference call to update on clinical and drug development plans on May 17th.
- Developing two therapeutic platforms: MYMD-1 for autoimmune diseases and Supera-CBD targeting key receptors in the CBD market.
- Risks associated with obtaining regulatory approvals for its pharmaceutical candidates.
- Potential impact from increased competition and the ongoing COVID-19 pandemic.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced it will host a conference call at 4:15 p.m. Eastern time on Monday, May 17th to provide an update on its clinical and drug development plan.
To participate in the briefing session, please click on the link below to register. Questions can be submitted in advance via the contact information below.
- Event Link: www.webcaster4.com/Webcast/Page/2584/41075
- Participant Dial In: Toll Free: 888-506-0062; International: 973-528-0011; Access Code: 592147
The conference call will also be available from the Investor Relations section of the Company's website at www.mymd.com and will be archived there shortly after the live event.
About MyMD Pharmaceuticals, Inc.
MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity. Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates, the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates, the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005563/en/
FAQ
What is the date of MyMD's upcoming conference call?
How can I participate in the MyMD conference call?
What are the main drug platforms being developed by MYMD?
What are the risks mentioned in MyMD's press release?
